Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$700,000 additional from institutional investor!
More good news today!!! Additional financing!!
Propanc Receives Additional $700,000 After Successful Completion of Animal Efficacy Studies
November 30, 2015
MELBOURNE, AUSTRALIA / ACCESSWIRE / November 30, 2015 / Propanc Health Group Corporation (PPCH) ("Propanc" or "the Company"), an emerging healthcare company focusing on development of new and proprietary treatments for cancer patients suffering from pancreatic, ovarian and colorectal cancers, today announced theCompany received a further $700,000 tranche from an institutional investor in order to progress their lead product, PRP, towards human trials, after reporting positive animal efficacy data in pancreatic and ovarian cancers from recent animal studies.
A total of $1.9 million has been received since the Securities Purchase Agreement, Debenture and Warrant (the "Financing Documents") were was executed by both parties on October 28th.
A further $2.1 million of the investment amount may be paid (totaling $4 million), pending the achievement of certain milestones and equity conditions set forth in the Financing Documents, as described in the Company's recent filings.
The aggregate deal size provides sufficient capital to cover future research and development activities leading up to the preparation and commencement of human trials for their lead product, PRP, and is expected to sufficiently cover the Company's operations over the next 12 months.
"We are very pleased to receive the additional tranche of capital from our investor, which shows great faith in the Company's potential, whilst acknowledging the completion of some very significant milestones, recently," said James Nathanielsz, Propanc's Chief Executive Officer. "Our attention will now turn towards confirming our development pathway for PRP by meeting with several regulatory agencies for scientific advice. Now that we have sufficient capital for the near term, we remain focused on completing the necessary activities so we can take our lead product into human trials at the earliest opportunity."
About Propanc:
Propanc is currently focused on developing new cancer treatments for patients suffering from pancreatic and colorectal cancers. We have developed a formulation of anti-cancer compounds which exert a number of effects designed to control or prevent tumors from recurring and spreading throughout the body. Our products involve or employ proenzymes, which are inactive precursors of enzymes.
In the near term, we intend to target patients with limited remaining therapeutic options for the treatment of solid tumors such as colorectal or pancreatic tumors. In future, we intend to develop our lead product to treat (i) early stage cancer and (ii) pre-cancerous diseases and (iii) as a preventative measure for patients at risk of developing cancer based on genetic screening. For more information, visit: www.propanc.com.
Forward-looking Statements:
Certain of the matters discussed in this announcement involve risks and uncertainties including, without limitation, those regarding the Company's ability to establish and maintain the proprietary nature of its technology through the patent process, its ability to license from others patents and patent applications, if necessary, to develop certain products, its ability to implement its long range business plan for various applications of its technology, and its ability to enter into agreements with any necessary marketing and/or distribution partners for purposes of commercialization. This is not a solicitation to buy or sell securities and does not purport to be an analysis of the company's financial position. See Propanc's most recent Quarterly Report on Form 10-Q and related 8K filings.
Contact:
Bob Woods
CEOcast, Inc.
212-732-4300
rwoods@ceocast.com
Parker Mitchell
Regal Consulting LLC
702 – 575 – 9157
regalconsultingllc@gmail.com
SOURCE: Propanc Health Group Corporation
Strong close for Friday! .043, I would think run has to finally be upon us.
And what happened to your tank prediction for today Rake/JacobKdavis on yahoo?? You were wrong as you are now.
LOL!! Grandmas turkey sounds good right about now as I ponder the thought of PPCH going to new highs above .0135! GL Swamp!
PPCH is wanting to run bad! Hoping for a late day breakout to carry over into Friday after thanksgiving.
NEWS was great! PPCH will go up! Positive trials results, financing secured, regulatory meetings soon, human trials, lots of good stuff in the pipe!
Guys, this POS has already broken .01, remember last week or week before it was down to .0092 so its been in subbies and may go back from the looks of this turd!
This stock looks WORSE daily!!!
Would like to see this back above .044
?? Nothing normal about this junk tanking like this.
YIKES!!! Glad I dumped this POS at .0071
This stock looks absolutely HORRIBLE!!!
Moving up premarket .042/.043
Time to dump this turd!! Looks like the dilution will never let it move up!
Possible break of .05 today guys.
PPCH closed above 50 DMA! Up tommorow!
Well..Well..Rakeman AKA JacobKdavis on Yahoo!! Looks like I found out your other identity Rake over on yahoo as you bash the hell outta this stock using the same terminology! Its clear you have an agenda here and its not good! PPCH will continue tommorow ride up on the see thru equity news and $1.52 price target!
Rake move on and stop being bitter! Your getting close to the ignore button with your constant bashing, move along and let us have our joy, sorry you sold too soon, your loss!!
Lol, Rake a sore loser in the sidelines!! Up more tommorow!
Great close!! Insane volume for PPCH!!
POS diluting machine scam!!!!
Looking for massive short squeeze!
L2 anyone?
Hope we get an afternoon rally to take us above .05!
Would be to break .05 today!
I never sold Dip$hit cable puppy!!
If they kept target of $1.52, they know something big is happening! And might I add they gave that as a 12 month price target!!
PPS up! Rake Vanished!
She's flyin! That $1.52 price target was what took us to .13 before, combined with positive efficacy trials news now and financing, she should climb, we shall see.
Still calling for price target of $1.52!!
Looks like ignition is lit!!
Something surged the PPS yesterday evening. Don't listen to Rake on the filings, warrants at .60 cents means you would want the PPS at .60 so you can exercise the warrants.
This stock should be ready to run, why it hasn't already is beyond me.
ACCESSWIRE / November 23, 2015 / According to Global Analyst Reports, the world market for colorectal cancer is expected to reach $8.8 billion by 2020 and the global pancreatic cancer market is projected to exceed $1.2 billion by 2015.
Propanc Health Group Corporation (PPCH) is developing a drug that could take a major slice of both markets. PPCH is developing new and proprietary treatments for cancer patients suffering from pancreatic and colorectal cancers.
PPCH may end up like AEZS! 3.19 to 8.52!! Went from 4.58 today all the way to 8.52 on preclinical trials news and patent news!
Agree, big buys and PPS shot up end of trading day.
Going UP!
You are correct jandKsMoney. Cant exercise the warrants unless the stock pps is at .60 which is a longggg way from it.